After the Torrent Pharmaceutical deal, pharma firm Elder Pharmaceutical would focus on brand building and enter new therapeutics areas to drive growth.
"After Torrent Pharmaceuticals' Rs 2,004-crore acquisition deal, Elder Pharmaceuticals Ltd (EPL) plans to concentrate and build on its domestic business of anti-infectives, strengthen in-license portfolio and grow its business in the UK and in Europe. It is also exploring the possibility of entering new therapeutics areas," a company statement said here today.
"EPL expects an increase in its consolidated revenues and to re-structure and re-strategise brands and people. EPL would easily increase its revenues and profitability," Elder Pharmaceuticals Chairman and Managing Director Alok Saxena said in the statement.
Elder Pharma's anti-infectives division has been contributing more than 10 percent to the total revenue and has been registering annual growth of more than 12 per cent.
Formic and its line-extension Formic-O are the key revenue contributors to this division. Newly-launched Balofloxacin, MENY (Meropenem) and Formic OF are expected to boost revenues in this division, the release said.
The company plans to further strengthen its in-license portfolio and increase its presence in the Neurological [CNS] therapeutic and cardio-vascular segments.
EPL plans to concentrate its efforts to increase its presence in injectables and anti-infectives' segments to nearly triple the turnover of its retained business in the next three years. Elder's focus would be on creating a product in a therapeutic category and to establish brand leadership in that segment, apart from developing its own portfolio.
EPL also intends to increase its presence in the UK and Europe through its wholly owned subsidiaries, NeutraHealth PLC and Elder Biomeda EAD.
